Genedata Extends Lead Discovery Collaboration with Novartis
News May 16, 2006
Genedata’s agreement with Novartis includes round the clock support for the Genedata Screener® platform in Cambridge (MA), USA and Basel, Switzerland.
"Novartis sought an innovative partner to deliver advanced analysis and visualization tools for HTS analysis," explained Dr. Stephan Heyse, Head of Screener.
The collaboration with Genedata was initiated with Novartis Discovery Technologies, a core component of the NIBR.
Novartis cultivates close development partnerships through its Discovery Technologies program.
Successful collaborations are scaled-up and applied at the Company’s research sites globally.
Scientists at Novartis use Screener to pinpoint quality issues in screening data as part of a highly automated analysis workflow. The software is designed to validate entire screens in a standardized fashion.
Dr. Heyse added, "This saves time and minimizes the risk that lead compounds fail at later phases of drug development."
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE